Möchten Sie immer auf dem neuesten Stand bleiben?

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO...

Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors...

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Immuneering to Present at the Leerink Global Healthcare Conference

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Janu

- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million...

- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday,...